v3.26.1
Note 13 - Capital Stock - Outstanding Warrants (Details) - $ / shares
Jun. 30, 2026
Jan. 13, 2026
Dec. 31, 2025
Jun. 30, 2023
Number of shares issuable (in shares) 7,910,247   6,696,914  
Avenue Warrants 2023 [Member]        
Exercise price (in dollars per share) [1] $ 4.6014      
Number of shares issuable (in shares) [1] 150,000   150,000  
Tranche A Warrant [Member]        
Exercise price (in dollars per share) $ 22 [2]     $ 22
Number of shares issuable (in shares) 0 [2]   2,500,000 [2] 2,500,000
Tranche B Warrant [Member]        
Exercise price (in dollars per share) [3] $ 30      
Number of shares issuable (in shares) [3] 2,500,000   2,500,000  
Common Stock Warrant [Member]        
Exercise price (in dollars per share) [4] $ 4.82      
Number of shares issuable (in shares) [4] 1,546,914   1,546,914  
Series A Warrants [Member]        
Exercise price (in dollars per share) $ 6 [5] $ 6    
Number of shares issuable (in shares) 1,114,000 [5] 1,114,000 0 [5]  
Series B Warrants [Member]        
Exercise price (in dollars per share) $ 6 [6] $ 6    
Number of shares issuable (in shares) 2,599,333 [6] 2,599,333 0 [6]  
[1] We issued the 2023 Avenue Warrant pursuant to a loan with Avenue (see Note 12). As of June 30, 2026 and December 31, 2025, the 2023 Avenue Warrant had not been exercised.
[2] We issued the Tranche A Warrants in a June 2023 public equity offering. Each Tranche A Warrant was exercisable for one share of our common stock. The Tranche A Warrants expired unexercised on June 16, 2026.
[3] We issued warrants in a June 2023 public equity offering (the “Tranche B Warrants”). Each Tranche B Warrant is exercisable for one share of our common stock. The Tranche B Warrants expire on the earlier of (i) 60 days following the date of our public announcement that an NDA for CNM-Au8 has been approved by the FDA, or (ii) June 16, 2030. As of June 30, 2026 and December 31, 2025, no Tranche B Warrants had been exercised.
[4] We issued the 2024 Common Warrants in an October 2024 public equity offering. Each 2024 Common Warrant is exercisable for one share of our common stock. As of June 30, 2026 and December 31, 2025, no 2024 Common Warrants had been exercised.
[5] We issued the Series A Warrants in a January 2026 public equity offering. Each Series A Warrant is exercisable for 1.2 shares of our common stock. The Series A Warrants expire three years from issuance unless, if on or after the first trading day immediately following the Series A Price Measurement Date, the closing price of our common stock is in-the-money, then we shall have the right, for a period of seven business days (such seventh day, the “Call Date”) following such trading date, to redeem or call for cancellation all or any portion of the Series A Warrants for which a notice of exercise has not yet been delivered for consideration equal to $0.01 per share (the “Redemption Price”). Any portion not exercised by 5:00 p.m. Eastern Time on the Call Date shall be automatically redeemed by us for the Redemption Price and shall thereafter be null and void. As of June 30, 2026, no Series A Warrants had been exercised.
[6] We issued the Series B Warrants in a January 2026 public equity offering. Each Series B Warrant is exercisable for 2.8 shares of our common stock. The Series B Warrants expire five years from issuance unless, if on or after the first trading day immediately following the Series B Price Measurement Date, the closing price of our common stock is in-the-money, then we shall have the right, for a period of seven business days following such trading date, to redeem or call for cancellation all or any portion of the Series B Warrants for which a notice of exercise has not yet been delivered for the Redemption Price. Any portion not exercised by 5:00 p.m. Eastern Time on the Call Date shall be automatically redeemed by us for the Redemption Price and shall thereafter be null and void. As of June 30, 2026, no Series B Warrants had been exercised.